199 related articles for article (PubMed ID: 38403587)
1. Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors.
Muñoz-Galván S; Verdugo-Sivianes EM; Santos-Pereira JM; Estevez-García P; Carnero A
J Exp Clin Cancer Res; 2024 Feb; 43(1):57. PubMed ID: 38403587
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor-2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.
He M; Wu H; Jiang Q; Liu Y; Han L; Yan Y; Wei B; Liu F; Deng X; Chen H; Zhao L; Wang M; Wu X; Yao W; Zhao H; Chen J; Wei M
Mol Oncol; 2019 Feb; 13(2):403-421. PubMed ID: 30536571
[TBL] [Abstract][Full Text] [Related]
3. The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer.
Nozawa-Suzuki N; Nagasawa H; Ohnishi K; Morishige K
Biochem Biophys Res Commun; 2015 Feb; 457(4):706-11. PubMed ID: 25619133
[TBL] [Abstract][Full Text] [Related]
4. HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways.
Yan Y; Liu F; Han L; Zhao L; Chen J; Olopade OI; He M; Wei M
J Exp Clin Cancer Res; 2018 Oct; 37(1):256. PubMed ID: 30340507
[TBL] [Abstract][Full Text] [Related]
5. Ursolic acid inhibits proliferation and reverses drug resistance of ovarian cancer stem cells by downregulating ABCG2 through suppressing the expression of hypoxia-inducible factor-1α in vitro.
Wang WJ; Sui H; Qi C; Li Q; Zhang J; Wu SF; Mei MZ; Lu YY; Wan YT; Chang H; Guo PT
Oncol Rep; 2016 Jul; 36(1):428-40. PubMed ID: 27221674
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor 1 alpha promotes cancer stem cells-like properties in human ovarian cancer cells by upregulating SIRT1 expression.
Qin J; Liu Y; Lu Y; Liu M; Li M; Li J; Wu L
Sci Rep; 2017 Sep; 7(1):10592. PubMed ID: 28878214
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia induced paclitaxel resistance in human ovarian cancers via hypoxia-inducible factor 1alpha.
Huang L; Ao Q; Zhang Q; Yang X; Xing H; Li F; Chen G; Zhou J; Wang S; Xu G; Meng L; Lu Y; Ma D
J Cancer Res Clin Oncol; 2010 Mar; 136(3):447-56. PubMed ID: 19760195
[TBL] [Abstract][Full Text] [Related]
9. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
10. IL-6 promotes nuclear translocation of HIF-1α to aggravate chemoresistance of ovarian cancer cells.
Xu S; Yu C; Ma X; Li Y; Shen Y; Chen Y; Huang S; Zhang T; Deng W; Wang Y
Eur J Pharmacol; 2021 Mar; 894():173817. PubMed ID: 33345849
[TBL] [Abstract][Full Text] [Related]
11. HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.
Ma S; Wang J; Cui Z; Yang X; Cui X; Li X; Zhao L
Sci Rep; 2024 Feb; 14(1):3870. PubMed ID: 38365849
[TBL] [Abstract][Full Text] [Related]
12. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
13. Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer.
Lu T; Tang J; Shrestha B; Heath BR; Hong L; Lei YL; Ljungman M; Neamati N
Theranostics; 2020; 10(15):6959-6976. PubMed ID: 32550915
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia Promotes Pancreatic Cancer Cell Dedifferentiation to Stem-Like Cell Phenotypes With High Tumorigenic Potential by the HIF-1α/Notch Signaling Pathway.
Mu R; Zou YK; Tu K; Wang DB; Tang D; Yu Z; Zhao L
Pancreas; 2021 May-Jun 01; 50(5):756-765. PubMed ID: 34016895
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-NOTCH1-SOX2 signaling is important for maintaining cancer stem cells in ovarian cancer.
Seo EJ; Kim DK; Jang IH; Choi EJ; Shin SH; Lee SI; Kwon SM; Kim KH; Suh DS; Kim JH
Oncotarget; 2016 Aug; 7(34):55624-55638. PubMed ID: 27489349
[TBL] [Abstract][Full Text] [Related]
17. The ST6Gal-I sialyltransferase protects tumor cells against hypoxia by enhancing HIF-1α signaling.
Jones RB; Dorsett KA; Hjelmeland AB; Bellis SL
J Biol Chem; 2018 Apr; 293(15):5659-5667. PubMed ID: 29475939
[TBL] [Abstract][Full Text] [Related]
18. Endothelial deletion of phospholipase D2 reduces hypoxic response and pathological angiogenesis.
Ghim J; Moon JS; Lee CS; Lee J; Song P; Lee A; Jang JH; Kim D; Yoon JH; Koh YJ; Chelakkot C; Kang BJ; Kim JM; Kim KL; Yang YR; Kim Y; Kim SH; Hwang D; Suh PG; Koh GY; Kong YY; Ryu SH
Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1697-703. PubMed ID: 24947526
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia-inducible factor 1-alpha up-regulates the expression of phospholipase D2 in colon cancer cells under hypoxic conditions.
Liu M; Du K; Fu Z; Zhang S; Wu X
Med Oncol; 2015 Jan; 32(1):394. PubMed ID: 25432699
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of CD133-Sustained Chemoresistant Cancer Stem-Like Cells in Human Ovarian Carcinoma.
Liu CL; Chen YJ; Fan MH; Liao YJ; Mao TL
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]